Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE)

NCT04265755 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04265755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04265755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE)
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
October 26, 2020
Completion date
January 18, 2023
Enrollment
1,406 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

migraine